Abstract:Modern natural products (NPs) research relies on untargeted liquid chromatography coupled with mass spectrometry metabolomics. Together with cutting-edge processing and computational annotation strategies, such approaches can yield extensive spectral and structural information. However, current processing workflows require feature-alignment steps based on retention time which hinders the comparison of samples originating from different batches or analyzed using different instrumental setups. In addition, there is currently no analytical framework available to efficiently match processed metabolomics data and associated metadata with external resources. To address these limitations, we present a new sample-centric and knowledge-driven framework allowing multi-modal data alignment - e.g. through chemical structures, biological activities, or spectral features - and demonstrate its value in exploring large and chemodiverse natural extract datasets. Here, the experimental data is processed at the sample level, matched with external identifiers when possible, semantically enriched, and integrated into a unified knowledge graph. The use of semantic web technology enables comparison of processed and standardized data, information, and knowledge at the repository scale. We demonstrate the utility of the developed framework, the Experimental Natural Products Knowledge Graph (ENPKG), to leverage the results obtained from screening 1,600 plant extracts against trypanosomatids and streamline the identification of new antiparasitic compounds. Thanks to its versatility, the proposed approach allows for a radically novel exploitation of metabolomics data. Semantic web technologies are a fundamental asset and we anticipate that their adoption will strongly complement the current computational metabolomics pipelines and enable the community to advance in the description of global chemodiversity and drug discovery projects.

Discovery of a novel pseudo-natural product Aurora kinase inhibitor chemotype through morphological profiling

Design, Synthesis, and Phenotypic Profiling of Pyrano‐Furo‐Pyridone Pseudo Natural Products

Identification of Readily Available Pseudo-Natural Products

Pseudo Natural Products—Chemical Evolution of Natural Product Structure

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

A highly enantioselective intramolecular 1,3-dipolar cycloaddition yields novel pseudo-natural product inhibitors of the Hedgehog signaling pathway

Principle and design of pseudo-natural products

Natural products fragment-based design and synthesis of a novel pentacyclic ring system as potential MAPK Inhibitor

Natural product fragment combination to performance-diverse pseudo-natural products

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Discovery of N -benzylbenzamide-based allosteric inhibitors of Aurora kinase A

Deliberations on Natural Products and Future Directions in the Pharmaceutical Industry

Prospecting for natural products by genome mining and microcrystal electron diffraction

Scaffold overlay of flavonoid-inspired molecules: Discovery of 2,3-diaryl-pyridopyrimidin-4-imine/ones as dual hTopo-II and tubulin targeting anticancer agents

Integrated Thermal Proteome Profiling and Affinity Ultrafiltration Mass Spectrometry (iTPAUMS): A Novel Paradigm for Elucidating the Mechanism of Action of Natural Products

2-Phenoxy-3, 4′-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization

Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold

A Sample-Centric and Knowledge-Driven Computational Framework for Natural Products Drug Discovery

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R

Selective Aurora A-TPX2 interaction inhibitors have efficacy as targeted anti-mitotic agents